For example, treatment with gefitinib or erlotinib, a TKI for EGFR, causes enhanced apoptosis in several cancer cells in vitro [3-5] or in xenograft tumor growths from breast cancer patients [6] and EGFR-dependent non-small cell lung cancer (NSCLC) cells [7], respectively. This evidence concerns the gene EGFR and non-small cell lung carcinoma.